Lasting increases in trait mindfulness after psilocybin correlate positively with the mystical-type experience in healthy individuals
Psilocybin-induced mystical-type experiences are associated with lasting positive psychological outcomes. Recent studies indicate that trait mindfulness is increased 3 months after psilocybin intake, preceded by decreases in neocortical serotonin 2A receptor (5-HT R) binding. However, the associatio...
Gespeichert in:
| Veröffentlicht in: | Frontiers in psychology Jg. 13; S. 948729 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
Switzerland
Frontiers Media S.A
05.10.2022
|
| Schlagworte: | |
| ISSN: | 1664-1078, 1664-1078 |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Psilocybin-induced mystical-type experiences are associated with lasting positive psychological outcomes. Recent studies indicate that trait mindfulness is increased 3 months after psilocybin intake, preceded by decreases in neocortical serotonin 2A receptor (5-HT
R) binding. However, the association between psilocybin-induced mystical-type experiences and subsequent changes in trait mindfulness remains unexplored, as does the association between pre-drug trait mindfulness and 5-HT
R binding in the healthy brain.
We evaluated whether psilocybin induced lasting increases in trait mindfulness in healthy volunteers, and whether the mystical-type experience was associated with this increase. We further examined the association between pre-drug trait mindfulness and 5-HT
R binding in neocortex and selected frontolimbic regions.
Forty-six medium-high dose psilocybin sessions were conducted in 39 healthy individuals. The mystical-type experience was measured with the Mystical Experience Questionnaire (MEQ) at the end of the session. Trait mindfulness was measured using the Mindful Attention and Awareness Scale (MAAS) at baseline and 3 months after the psilocybin session. Thirty-two of the participants completed pre-drug [
C]-Cimbi-36 positron emission tomography (PET) to assess 5-HT
R binding in neocortex and,
, in the frontolimbic regions amygdala, frontal cortex, and anterior cingulate cortex.
The MAAS score was significantly increased at 3-month follow-up (
= 3.24 × 10
), a change positively associated with the MEQ score (
= 0.035). Although the association between pre-drug MAAS score and neocortex 5-HT
R binding was not significant (
= 0.24),
analyses revealed a significant negative association between MAAS and right amygdala 5-HT
R binding (p
= 0.008).
We here show that lasting changes in trait mindfulness following psilocybin administration are positively associated with intensity of the mystical-type experience, suggesting that the acute phenomenology of psilocybin facilitates a shift in awareness conducive for mindful living. We furthermore show that higher pre-drug trait mindfulness is associated with reduced 5-HT
R binding in the right amygdala. |
|---|---|
| AbstractList | Psilocybin-induced mystical-type experiences are associated with lasting positive psychological outcomes. Recent studies indicate that trait mindfulness is increased 3 months after psilocybin intake, preceded by decreases in neocortical serotonin 2A receptor (5-HT
R) binding. However, the association between psilocybin-induced mystical-type experiences and subsequent changes in trait mindfulness remains unexplored, as does the association between pre-drug trait mindfulness and 5-HT
R binding in the healthy brain.
We evaluated whether psilocybin induced lasting increases in trait mindfulness in healthy volunteers, and whether the mystical-type experience was associated with this increase. We further examined the association between pre-drug trait mindfulness and 5-HT
R binding in neocortex and selected frontolimbic regions.
Forty-six medium-high dose psilocybin sessions were conducted in 39 healthy individuals. The mystical-type experience was measured with the Mystical Experience Questionnaire (MEQ) at the end of the session. Trait mindfulness was measured using the Mindful Attention and Awareness Scale (MAAS) at baseline and 3 months after the psilocybin session. Thirty-two of the participants completed pre-drug [
C]-Cimbi-36 positron emission tomography (PET) to assess 5-HT
R binding in neocortex and,
, in the frontolimbic regions amygdala, frontal cortex, and anterior cingulate cortex.
The MAAS score was significantly increased at 3-month follow-up (
= 3.24 × 10
), a change positively associated with the MEQ score (
= 0.035). Although the association between pre-drug MAAS score and neocortex 5-HT
R binding was not significant (
= 0.24),
analyses revealed a significant negative association between MAAS and right amygdala 5-HT
R binding (p
= 0.008).
We here show that lasting changes in trait mindfulness following psilocybin administration are positively associated with intensity of the mystical-type experience, suggesting that the acute phenomenology of psilocybin facilitates a shift in awareness conducive for mindful living. We furthermore show that higher pre-drug trait mindfulness is associated with reduced 5-HT
R binding in the right amygdala. Psilocybin-induced mystical-type experiences are associated with lasting positive psychological outcomes. Recent studies indicate that trait mindfulness is increased 3 months after psilocybin intake, preceded by decreases in neocortical serotonin 2A receptor (5-HT2AR) binding. However, the association between psilocybin-induced mystical-type experiences and subsequent changes in trait mindfulness remains unexplored, as does the association between pre-drug trait mindfulness and 5-HT2AR binding in the healthy brain.BackgroundPsilocybin-induced mystical-type experiences are associated with lasting positive psychological outcomes. Recent studies indicate that trait mindfulness is increased 3 months after psilocybin intake, preceded by decreases in neocortical serotonin 2A receptor (5-HT2AR) binding. However, the association between psilocybin-induced mystical-type experiences and subsequent changes in trait mindfulness remains unexplored, as does the association between pre-drug trait mindfulness and 5-HT2AR binding in the healthy brain.We evaluated whether psilocybin induced lasting increases in trait mindfulness in healthy volunteers, and whether the mystical-type experience was associated with this increase. We further examined the association between pre-drug trait mindfulness and 5-HT2AR binding in neocortex and selected frontolimbic regions.AimWe evaluated whether psilocybin induced lasting increases in trait mindfulness in healthy volunteers, and whether the mystical-type experience was associated with this increase. We further examined the association between pre-drug trait mindfulness and 5-HT2AR binding in neocortex and selected frontolimbic regions.Forty-six medium-high dose psilocybin sessions were conducted in 39 healthy individuals. The mystical-type experience was measured with the Mystical Experience Questionnaire (MEQ) at the end of the session. Trait mindfulness was measured using the Mindful Attention and Awareness Scale (MAAS) at baseline and 3 months after the psilocybin session. Thirty-two of the participants completed pre-drug [11C]-Cimbi-36 positron emission tomography (PET) to assess 5-HT2AR binding in neocortex and, post-hoc, in the frontolimbic regions amygdala, frontal cortex, and anterior cingulate cortex.Materials and methodsForty-six medium-high dose psilocybin sessions were conducted in 39 healthy individuals. The mystical-type experience was measured with the Mystical Experience Questionnaire (MEQ) at the end of the session. Trait mindfulness was measured using the Mindful Attention and Awareness Scale (MAAS) at baseline and 3 months after the psilocybin session. Thirty-two of the participants completed pre-drug [11C]-Cimbi-36 positron emission tomography (PET) to assess 5-HT2AR binding in neocortex and, post-hoc, in the frontolimbic regions amygdala, frontal cortex, and anterior cingulate cortex.The MAAS score was significantly increased at 3-month follow-up (p = 3.24 × 10-6), a change positively associated with the MEQ score (p = 0.035). Although the association between pre-drug MAAS score and neocortex 5-HT2AR binding was not significant (p = 0.24), post-hoc analyses revealed a significant negative association between MAAS and right amygdala 5-HT2AR binding (pFWER = 0.008).ResultsThe MAAS score was significantly increased at 3-month follow-up (p = 3.24 × 10-6), a change positively associated with the MEQ score (p = 0.035). Although the association between pre-drug MAAS score and neocortex 5-HT2AR binding was not significant (p = 0.24), post-hoc analyses revealed a significant negative association between MAAS and right amygdala 5-HT2AR binding (pFWER = 0.008).We here show that lasting changes in trait mindfulness following psilocybin administration are positively associated with intensity of the mystical-type experience, suggesting that the acute phenomenology of psilocybin facilitates a shift in awareness conducive for mindful living. We furthermore show that higher pre-drug trait mindfulness is associated with reduced 5-HT2AR binding in the right amygdala.ConclusionWe here show that lasting changes in trait mindfulness following psilocybin administration are positively associated with intensity of the mystical-type experience, suggesting that the acute phenomenology of psilocybin facilitates a shift in awareness conducive for mindful living. We furthermore show that higher pre-drug trait mindfulness is associated with reduced 5-HT2AR binding in the right amygdala. BackgroundPsilocybin-induced mystical-type experiences are associated with lasting positive psychological outcomes. Recent studies indicate that trait mindfulness is increased 3 months after psilocybin intake, preceded by decreases in neocortical serotonin 2A receptor (5-HT2AR) binding. However, the association between psilocybin-induced mystical-type experiences and subsequent changes in trait mindfulness remains unexplored, as does the association between pre-drug trait mindfulness and 5-HT2AR binding in the healthy brain.AimWe evaluated whether psilocybin induced lasting increases in trait mindfulness in healthy volunteers, and whether the mystical-type experience was associated with this increase. We further examined the association between pre-drug trait mindfulness and 5-HT2AR binding in neocortex and selected frontolimbic regions.Materials and methodsForty-six medium-high dose psilocybin sessions were conducted in 39 healthy individuals. The mystical-type experience was measured with the Mystical Experience Questionnaire (MEQ) at the end of the session. Trait mindfulness was measured using the Mindful Attention and Awareness Scale (MAAS) at baseline and 3 months after the psilocybin session. Thirty-two of the participants completed pre-drug [11C]-Cimbi-36 positron emission tomography (PET) to assess 5-HT2AR binding in neocortex and, post-hoc, in the frontolimbic regions amygdala, frontal cortex, and anterior cingulate cortex.ResultsThe MAAS score was significantly increased at 3-month follow-up (p = 3.24 × 10–6), a change positively associated with the MEQ score (p = 0.035). Although the association between pre-drug MAAS score and neocortex 5-HT2AR binding was not significant (p = 0.24), post-hoc analyses revealed a significant negative association between MAAS and right amygdala 5-HT2AR binding (pFWER = 0.008).ConclusionWe here show that lasting changes in trait mindfulness following psilocybin administration are positively associated with intensity of the mystical-type experience, suggesting that the acute phenomenology of psilocybin facilitates a shift in awareness conducive for mindful living. We furthermore show that higher pre-drug trait mindfulness is associated with reduced 5-HT2AR binding in the right amygdala. |
| Author | Fisher, Patrick MacDonald Armand, Sophia Ozenne, Brice Madsen, Martin Korsbak Stenbæk, Dea Siggaard Søndergaard, Anna Knudsen, Gitte Moos |
| AuthorAffiliation | 2 Institute of Clinical Medicine, University of Copenhagen , Copenhagen , Denmark 4 Section of Biostatistics, Department of Public Health, University of Copenhagen , Copenhagen , Denmark 5 Institute of Psychology, University of Copenhagen , Copenhagen , Denmark 1 Neurobiology Research Unit and NeuroPharm, Copenhagen University Hospital Rigshospitalet , Copenhagen , Denmark 3 Department of Psychiatry, University Hospital Svendborg , Svendborg , Denmark |
| AuthorAffiliation_xml | – name: 2 Institute of Clinical Medicine, University of Copenhagen , Copenhagen , Denmark – name: 4 Section of Biostatistics, Department of Public Health, University of Copenhagen , Copenhagen , Denmark – name: 3 Department of Psychiatry, University Hospital Svendborg , Svendborg , Denmark – name: 5 Institute of Psychology, University of Copenhagen , Copenhagen , Denmark – name: 1 Neurobiology Research Unit and NeuroPharm, Copenhagen University Hospital Rigshospitalet , Copenhagen , Denmark |
| Author_xml | – sequence: 1 givenname: Anna surname: Søndergaard fullname: Søndergaard, Anna – sequence: 2 givenname: Martin Korsbak surname: Madsen fullname: Madsen, Martin Korsbak – sequence: 3 givenname: Brice surname: Ozenne fullname: Ozenne, Brice – sequence: 4 givenname: Sophia surname: Armand fullname: Armand, Sophia – sequence: 5 givenname: Gitte Moos surname: Knudsen fullname: Knudsen, Gitte Moos – sequence: 6 givenname: Patrick MacDonald surname: Fisher fullname: Fisher, Patrick MacDonald – sequence: 7 givenname: Dea Siggaard surname: Stenbæk fullname: Stenbæk, Dea Siggaard |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36275302$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1ks9u1DAQxiNUREvpA3BBOXLJYjtOnFyQUMWfSitxgbM1sccbV9442M5CHoD3xtttUYuELzOyv_mN7fleFmeTn7AoXlOyqeuuf2fmuO42jDC26XknWP-suKBtyytKRHf2KD8vrmK8JXlxwghhL4rzumWiqQm7KH5vISY77Uo7qYAQMeasTAFsKvd20mZxE8ZYgkkYyjla59U6ZInyIaCDhOXso032gG4tf9o0lmnEcr9mqgJXpXXGEn_NGCxOCo_wEcGlcc2ptgerF3DxVfHc5IBX9_Gy-P7p47frL9X26-eb6w_bSvG2SdVgWAeDUFyA4HVPB9YAss4YxgY9UM2ZajUbmGr6VohBUexBaEOJQQ69hvqyuDlxtYdbOQe7h7BKD1bebfiwkxDyxR1K6HhNATqTm_CmVj1nWolWKNSdANNn1vsTa16GPWqFU_419wT69GSyo9z5g-ybjuTnZMDbe0DwPxaMSe5tVOgcTOiXKJlgHeVtnlWWvnnc62-ThzlmgTgJVPAxBjRS2QTJ-mNr6yQl8mgaeWcaeTSNPJkmV9J_Kh_g_6_5AyUiy90 |
| CitedBy_id | crossref_primary_10_1016_j_pharmthera_2024_108641 crossref_primary_10_1016_j_neubiorev_2025_106239 crossref_primary_10_1177_0271678X251323364 crossref_primary_10_1080_02791072_2024_2302186 crossref_primary_10_1007_s12671_025_02554_3 crossref_primary_10_1177_02698811241269669 crossref_primary_10_1007_s10608_025_10588_z crossref_primary_10_1038_s44184_023_00053_8 crossref_primary_10_1016_j_concog_2023_103536 crossref_primary_10_2196_54632 crossref_primary_10_1111_bph_70088 crossref_primary_10_1089_jicm_2023_0784 crossref_primary_10_1177_02698811251319457 crossref_primary_10_1007_s00406_023_01699_3 crossref_primary_10_1089_psymed_2024_0039 crossref_primary_10_1016_j_jpsychires_2025_09_007 crossref_primary_10_1016_j_nsa_2023_103929 |
| Cites_doi | 10.1073/pnas.1112029108 10.1093/clipsy/bpg016 10.1177/0269881116675512 10.3389/fpsyt.2020.00224 10.1523/JNEUROSCI.2852-09.2010 10.1124/pr.115.011478 10.1523/JNEUROSCI.2830-16.2016 10.1177/0269881117731279 10.1177/0269881120959609 10.1002/hbm.25138 10.1016/j.neuroimage.2004.10.017 10.1007/BF00634454 10.1016/j.jcbs.2019.11.002 10.1177/1948550610396585 10.1080/02791072.2022.2060773 10.4088/JCP.v67n1110 10.1038/npp.2017.84 10.1007/s00213-006-0457-5 10.1007/s00213-019-05236-w 10.1016/S2215-0366(16)30065-7 10.1038/s41386-019-0324-9 10.1177/0269881114565144 10.1001/archpsyc.56.8.705 10.1016/j.neubiorev.2016.03.021 10.1371/journal.pone.0030800 10.1038/jcbfm.2014.68 10.1016/j.paid.2009.06.026 10.1016/j.cpr.2011.04.006 10.1016/j.neuroimage.2019.04.009 10.3389/fnhum.2014.00020 10.1007/s00213-015-4162-0 10.1080/17512433.2021.1933434 10.1093/clipsy/bph077 10.3389/fphar.2022.841648 10.1007/s00213-017-4771-x 10.1016/j.brat.2005.06.006 10.1037/pas0000196 10.1007/7854_2017_474 10.1177/0269881114548296 10.1093/scan/nsm030 10.3389/fphar.2017.00974 10.1002/hbm.25946 10.1037/a0018312 10.1056/nejmoa2032994 10.1001/archgenpsychiatry.2010.116 10.1016/j.ejphar.2008.07.011 10.1016/j.euroneuro.2021.06.001 10.1037/a0024931 10.3389/fnhum.2017.00245 10.1038/s41598-019-50612-3 10.1007/s00213-018-4988-3 10.1177/1745691611419671 10.3389/fpsyg.2018.01475 10.3389/fpsyt.2021.707057 10.1177/0269881111420188 10.1001/jamapsychiatry.2020.3285 10.1111/acps.13249 10.1177/1073191105283504 10.1016/j.neuroimage.2016.02.001 10.1177/0269881115609019 10.1177/0269881119845793 10.1177/0269881108094300 10.1007/7854_2016_459 10.1037/0022-3514.84.4.822 10.1016/j.biopsych.2007.07.009 10.1177/0271678X16629483 10.1016/S0361-9230(01)00623-2 10.1073/pnas.1119598109 10.1016/j.euroneuro.2020.02.001 10.1002/jclp.20761 10.1177/0269881116675513 10.3109/00952990.2016.1170135 10.1016/j.neuroimage.2013.08.035 10.1007/s00213-011-2358-5 10.1371/journal.pone.0127447 10.1097/00001756-199812010-00024 |
| ContentType | Journal Article |
| Copyright | Copyright © 2022 Søndergaard, Madsen, Ozenne, Armand, Knudsen, Fisher and Stenbæk. Copyright © 2022 Søndergaard, Madsen, Ozenne, Armand, Knudsen, Fisher and Stenbæk. 2022 Søndergaard, Madsen, Ozenne, Armand, Knudsen, Fisher and Stenbæk |
| Copyright_xml | – notice: Copyright © 2022 Søndergaard, Madsen, Ozenne, Armand, Knudsen, Fisher and Stenbæk. – notice: Copyright © 2022 Søndergaard, Madsen, Ozenne, Armand, Knudsen, Fisher and Stenbæk. 2022 Søndergaard, Madsen, Ozenne, Armand, Knudsen, Fisher and Stenbæk |
| DBID | AAYXX CITATION NPM 7X8 5PM DOA |
| DOI | 10.3389/fpsyg.2022.948729 |
| DatabaseName | CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) Directory of Open Access Journals |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Psychology |
| EISSN | 1664-1078 |
| ExternalDocumentID | oai_doaj_org_article_a8431aa8fb25453c942dc767ced87af9 PMC9580465 36275302 10_3389_fpsyg_2022_948729 |
| Genre | Journal Article |
| GroupedDBID | 53G 5VS 9T4 AAFWJ AAKDD AAYXX ABIVO ACGFO ACGFS ACHQT ADBBV ADRAZ AEGXH AFPKN AIAGR ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV CITATION DIK EBS EJD EMOBN F5P GROUPED_DOAJ GX1 HYE KQ8 M48 M~E O5R O5S OK1 P2P PGMZT RNS RPM ACXDI IPNFZ NPM RIG 7X8 5PM |
| ID | FETCH-LOGICAL-c465t-bf28ab7c47a74391b25ae28ff22bdb1d42c6d2b2c59677bc1e9a7df10fe4a9da3 |
| IEDL.DBID | DOA |
| ISICitedReferencesCount | 21 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000874184900001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1664-1078 |
| IngestDate | Fri Oct 03 12:51:03 EDT 2025 Thu Aug 21 18:39:42 EDT 2025 Wed Nov 12 06:14:49 EST 2025 Thu Apr 03 07:04:27 EDT 2025 Sat Nov 29 02:53:10 EST 2025 Tue Nov 18 22:00:32 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | psychedelics serotonin 2A receptor [11C]-Cimbi-36 mindfulness mystical experience psilocybin Mindful Attention and Awareness Scale |
| Language | English |
| License | Copyright © 2022 Søndergaard, Madsen, Ozenne, Armand, Knudsen, Fisher and Stenbæk. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c465t-bf28ab7c47a74391b25ae28ff22bdb1d42c6d2b2c59677bc1e9a7df10fe4a9da3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Reviewed by: Kai-Chun Yang, Taipei Veterans General Hospital, Taiwan; Yasmin Schmid, University of California, San Diego, United States; Szabolcs Lehel, Rigshospitalet, Denmark This article was submitted to Psychology for Clinical Settings, a section of the journal Frontiers in Psychology Edited by: Nuno Conceicao, University of Lisbon, Portugal |
| OpenAccessLink | https://doaj.org/article/a8431aa8fb25453c942dc767ced87af9 |
| PMID | 36275302 |
| PQID | 2728146362 |
| PQPubID | 23479 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_a8431aa8fb25453c942dc767ced87af9 pubmedcentral_primary_oai_pubmedcentral_nih_gov_9580465 proquest_miscellaneous_2728146362 pubmed_primary_36275302 crossref_citationtrail_10_3389_fpsyg_2022_948729 crossref_primary_10_3389_fpsyg_2022_948729 |
| PublicationCentury | 2000 |
| PublicationDate | 2022-10-05 |
| PublicationDateYYYYMMDD | 2022-10-05 |
| PublicationDate_xml | – month: 10 year: 2022 text: 2022-10-05 day: 05 |
| PublicationDecade | 2020 |
| PublicationPlace | Switzerland |
| PublicationPlace_xml | – name: Switzerland |
| PublicationTitle | Frontiers in psychology |
| PublicationTitleAlternate | Front Psychol |
| PublicationYear | 2022 |
| Publisher | Frontiers Media S.A |
| Publisher_xml | – name: Frontiers Media S.A |
| References | Carhart-Harris (B12) 2017; 42 Griffiths (B31) 2016; 30 Griffiths (B35) 2006; 187 Ettrup (B22) 2014; 34 Kabat-Zinn (B47) 1990 Heuschkel (B39) 2020; 11 Jørgensen (B46) 2018; 37 Way (B82) 2010; 10 Smigielski (B72); 196 Armand (B2) 2022; 43 Qiu (B63) 2022 Jensen (B42) 2016; 28 Ettrup (B23) 2016; 130 Svarer (B78) 2005; 24 Brown (B10) 2003; 84 Pahnke (B61) 1963 Spies (B74) 2020; 41 Griffiths (B34) 2008; 22 Hayes (B38) 2006; 44 Beliveau (B6) 2017; 37 Smigielski (B71); 9 Shapiro (B68) 2011; 67 Keng (B49) 2011; 31 Muthukumaraswamy (B59) 2021; 14 Nichols (B60) 2016; 68 Gray (B30) 2001; 56 Finnema (B25) 2014; 84 Carhart-Harris (B15) 2012; 109 Grob (B36) 2011; 68 Kiken (B50) 2011; 2 Günther (B37) 2009; 593 Sanders-Bush (B66) 1989; 99 Eleftheriou (B20) 2021; 12 Barrett (B5) 2015; 29 Uthaug (B79) 2019; 236 Johnson (B44) 2017; 43 Brewer (B9) 2011; 108 Carhart-Harris (B14) 2016; 3 Carhart-Harris (B17) 2014; 8 Barrett (B4) 2018 McCulloch (B55) 2022; 13 Farb (B24) 2007; 2 Stenbæk (B76) 2020; 35 Uthaug (B80) 2018; 235 Bishop (B7) 2004; 11 Griffiths (B32) 2018; 32 Davis (B19) 2021; 78 Soler (B73) 2016; 233 Kabat-Zinn (B48) 2003; 10 Fox (B26) 2016; 65 Andersen (B1) 2021; 143 Garcia-Romeu (B28) 2019; 33 Studerus (B77) 2012; 7 Frokjaer (B27) 2008; 63 Madsen (B52) 2019; 44 Maclean (B51) 2011; 25 Vollenweider (B81) 1998; 9 Cohen (B18) 1988 Segal (B67) 2002 Griffiths (B33) 2011; 218 Millière (B57) 2018; 9 Yatham (B83) 1999; 56 Millière (B56) 2017; 11 Carhart-Harris (B13) 2018; 235 Giluk (B29) 2009; 47 Sheehan (B69) 1998; 59 Jensen (B43) 2012; 141 Carhart-Harris (B16) 2021; 384 Hölzel (B41) 2011; 6 Madsen (B54) 2021; 50 Erritzoe (B21) 2010; 30 Bogenschutz (B8) 2015; 29 Preller (B62) 2018 Johnson (B45) 2014; 28 Sloshower (B70) 2020; 15 Camilleri (B11) 2015; 10 Roseman (B64) 2018; 8 Ross (B65) 2016; 30 Baer (B3) 2006; 13 Madsen (B53) 2020; 33 Hölzel (B40) 2006; 38 Stace (B75) 1960 Moreno (B58) 2006; 67 |
| References_xml | – volume: 108 start-page: 20254 year: 2011 ident: B9 article-title: Meditation experience is associated with differences in default mode network activity and connectivity. publication-title: Proc. Natl. Acad. Sci. U.S.A. doi: 10.1073/pnas.1112029108 – volume: 10 start-page: 144 year: 2003 ident: B48 article-title: Mindfulness-based interventions in context: Past, present, and future. publication-title: Clin. Psychol. Sci. Pract. doi: 10.1093/clipsy/bpg016 – volume: 30 start-page: 1165 year: 2016 ident: B65 article-title: Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. publication-title: J. Psychopharmacol. doi: 10.1177/0269881116675512 – volume: 11 start-page: 224 year: 2020 ident: B39 article-title: Depression, mindfulness, and psilocybin: Possible complementary effects of mindfulness meditation and psilocybin in the treatment of depression. A review. publication-title: Front. Psychiatry doi: 10.3389/fpsyt.2020.00224 – volume: 30 start-page: 3391 year: 2010 ident: B21 article-title: A nonlinear relationship between cerebral serotonin transporter and 5HT-2A receptor binding: An in vivo molecular imaging study in humans. publication-title: J. Neurosci. doi: 10.1523/JNEUROSCI.2852-09.2010 – volume: 68 start-page: 264 year: 2016 ident: B60 article-title: Psychedelics. publication-title: Pharmacol. Rev. doi: 10.1124/pr.115.011478 – volume: 37 start-page: 120 year: 2017 ident: B6 article-title: A high-resolution in vivo atlas of the human brain’s serotonin system. publication-title: J. Neurosci. doi: 10.1523/JNEUROSCI.2830-16.2016 – volume: 32 start-page: 49 year: 2018 ident: B32 article-title: Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors. publication-title: J. Psychopharmacol. doi: 10.1177/0269881117731279 – volume: 35 start-page: 459 year: 2020 ident: B76 article-title: Brain serotonin 2A receptor binding predicts subjective temporal and mystical effects of psilocybin in healthy humans. publication-title: J. Psychopharmacol. doi: 10.1177/0269881120959609 – volume: 41 start-page: 4518 year: 2020 ident: B74 article-title: Common HTR2A variants and 5-HTTLPR are not associated with human in vivo serotonin 2A receptor levels. publication-title: Hum. Brain Mapp. doi: 10.1002/hbm.25138 – volume: 59 start-page: 22 year: 1998 ident: B69 article-title: The Mini-International Neuropsychiatric Interview (M.I.N.I.): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. publication-title: J. Clin. Psychiatry – volume: 24 start-page: 969 year: 2005 ident: B78 article-title: MR-based automatic delineation of volumes of interest in human brain PET images using probability maps. publication-title: Neuroimage doi: 10.1016/j.neuroimage.2004.10.017 – volume: 99 start-page: 64 year: 1989 ident: B66 article-title: Sertraline-induced desensitization of the serotonin 5HT-2 receptor transmembrane sig- naling system. publication-title: Psychopharmacology (Berl.) doi: 10.1007/BF00634454 – volume: 15 start-page: 12 year: 2020 ident: B70 article-title: Psilocybin-assisted therapy of major depressive disorder using Acceptance and Commitment Therapy as a therapeutic frame. publication-title: J. Context. Behav. Sci. doi: 10.1016/j.jcbs.2019.11.002 – volume: 2 start-page: 425 year: 2011 ident: B50 article-title: Looking up: Mindfulness increases positive judgments and reduces negativity bias. publication-title: Soc. Psychol. Personal. Sci. doi: 10.1177/1948550610396585 – start-page: 1 year: 2022 ident: B63 article-title: Psychedelic experiences and mindfulness are associated with improved wellbeing publication-title: J. Psychoactive Drugs doi: 10.1080/02791072.2022.2060773 – volume: 67 start-page: 1735 year: 2006 ident: B58 article-title: Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. publication-title: J. Clin. Psychiatry doi: 10.4088/JCP.v67n1110 – volume: 42 start-page: 2105 year: 2017 ident: B12 article-title: The therapeutic potential of psychedelic drugs: Past, present and future. publication-title: Neuropsychopharmacology doi: 10.1038/npp.2017.84 – volume: 187 start-page: 268 year: 2006 ident: B35 article-title: Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. publication-title: Psychopharmacology (Berl.) doi: 10.1007/s00213-006-0457-5 – volume: 236 start-page: 2653 year: 2019 ident: B79 article-title: A single inhalation of vapor from dried toad secretion containing 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in a naturalistic setting is related to sustained enhancement of satisfaction with life, mindfulness-related capacities, and a decrement of psyc. publication-title: Psychopharmacology (Berl.) doi: 10.1007/s00213-019-05236-w – volume: 3 start-page: 619 year: 2016 ident: B14 article-title: Psilocybin with psychological support for treatment-resistant depression: An open-label feasibility study. publication-title: Lancet Psychiatry doi: 10.1016/S2215-0366(16)30065-7 – volume: 44 start-page: 1328 year: 2019 ident: B52 article-title: Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels. publication-title: Neuropsychopharmacology doi: 10.1038/s41386-019-0324-9 – volume: 29 start-page: 289 year: 2015 ident: B8 article-title: Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study. publication-title: J. Psychopharmacol. doi: 10.1177/0269881114565144 – volume: 56 start-page: 705 year: 1999 ident: B83 article-title: Decrease in Brain Serotonin 2 Receptor Binding in Patients With Major Depression Following Desipramine Treatment A Positron Emission Tomography Study With Fluorine-18–Labeled Setoperone. publication-title: Arch Gen Psychiatry doi: 10.1001/archpsyc.56.8.705 – volume: 65 start-page: 208 year: 2016 ident: B26 article-title: Functional neuroanatomy of meditation: A review and meta-analysis of 78 functional neuroimaging investigations. publication-title: Neurosci. Biobehav. Rev. doi: 10.1016/j.neubiorev.2016.03.021 – year: 1990 ident: B47 publication-title: Full catastrophe living: Using the wisdom of your mind to face stress, pain and illness. – volume: 7 start-page: e30800 year: 2012 ident: B77 article-title: Prediction of psilocybin response in healthy volunteers. publication-title: PLoS One doi: 10.1371/journal.pone.0030800 – volume: 34 start-page: 1188 year: 2014 ident: B22 article-title: Serotonin 2A receptor agonist binding in the human brain with [11 C]Cimbi-36. publication-title: J. Cereb. Blood Flow Metab. doi: 10.1038/jcbfm.2014.68 – volume: 47 start-page: 805 year: 2009 ident: B29 article-title: Mindfulness, big five personality, and affect: A meta-analysis. publication-title: Pers. Individ. Dif. doi: 10.1016/j.paid.2009.06.026 – volume: 31 start-page: 1041 year: 2011 ident: B49 article-title: Effects of mindfulness on psychological health. publication-title: Clin. Psychol. Rev. doi: 10.1016/j.cpr.2011.04.006 – volume: 196 start-page: 207 ident: B72 article-title: Psilocybin-assisted mindfulness training modulates self-consciousness and brain default mode network connectivity with lasting effects. publication-title: Neuroimage doi: 10.1016/j.neuroimage.2019.04.009 – volume: 8 start-page: 20 year: 2014 ident: B17 article-title: The entropic brain: A theory of conscious states informed by neuroimaging research with psychedelic drugs. publication-title: Front. Hum. Neurosci. doi: 10.3389/fnhum.2014.00020 – volume: 233 start-page: 823 year: 2016 ident: B73 article-title: Exploring the therapeutic potential of Ayahuasca: Acute intake increases mindfulness-related capacities. publication-title: Psychopharmacology (Berl.) doi: 10.1007/s00213-015-4162-0 – volume: 14 start-page: 1133 year: 2021 ident: B59 article-title: Blinding and expectancy confounds in psychedelic randomized controlled trials. publication-title: Expert Rev. Clin. Pharmacol. doi: 10.1080/17512433.2021.1933434 – volume: 11 start-page: 230 year: 2004 ident: B7 article-title: Mindfulness: A proposed operational definition. publication-title: Clin. Psychol. Sci. Pract. doi: 10.1093/clipsy/bph077 – volume: 13 start-page: 841648 year: 2022 ident: B55 article-title: Psilocybin-induced mystical-type experiences are related to persisting positive effects: A quantitative and qualitative report. publication-title: Front. Pharmacol. doi: 10.3389/fphar.2022.841648 – volume: 235 start-page: 399 year: 2018 ident: B13 article-title: Psilocybin with psychological support for treatment-resistant depression: Six-month follow-up. publication-title: Psychopharmacology (Berl.) doi: 10.1007/s00213-017-4771-x – year: 1963 ident: B61 publication-title: Drugs and mysticism: An analysis of the relationship between psychedelic drugs and the mystical consciousness. Thesis presented to the President and Fellows of Harvard University for the Ph.D. thesis in Religion and Society. – volume: 44 start-page: 1 year: 2006 ident: B38 article-title: Acceptance and commitment therapy: Model, processes and outcomes. publication-title: Behav. Res. Ther. doi: 10.1016/j.brat.2005.06.006 – volume: 28 start-page: e70 year: 2016 ident: B42 article-title: General inattentiveness is a long-term reliable trait independently predictive of psychological health: Danish validation studies of the mindful attention awareness scale. publication-title: Psychol. Assess. doi: 10.1037/pas0000196 – start-page: 393 year: 2018 ident: B4 article-title: Classic hallucinogens and mystical experiences: Phenomenology and neural correlates publication-title: Behavioral neurobiology of psychedelic drugs. current topics in behavioral neurosciences doi: 10.1007/7854_2017_474 – volume: 28 start-page: 983 year: 2014 ident: B45 article-title: Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. publication-title: J. Psychopharmacol. doi: 10.1177/0269881114548296 – volume: 2 start-page: 313 year: 2007 ident: B24 article-title: Attending to the present: Mindfulness meditation reveals distinct neural modes of self-reference. publication-title: Soc. Cogn. Affect. Neurosci. doi: 10.1093/scan/nsm030 – volume: 8 start-page: 974 year: 2018 ident: B64 article-title: Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression. publication-title: Front. Pharmacol. doi: 10.3389/fphar.2017.00974 – volume: 43 start-page: 4174 year: 2022 ident: B2 article-title: Brain serotonin transporter is associated with cognitive-affective biases in healthy individuals. publication-title: Hum. Brain Mapp. doi: 10.1002/hbm.25946 – volume: 10 start-page: 12 year: 2010 ident: B82 article-title: Dispositional mindfulness and depressive symptomatology: Correlations with limbic and self-referential neural activity during rest. publication-title: Emotion doi: 10.1037/a0018312 – volume: 384 start-page: 1402 year: 2021 ident: B16 article-title: Trial of psilocybin versus escitalopram for depression. publication-title: N. Engl. J. Med. doi: 10.1056/nejmoa2032994 – volume: 68 start-page: 71 year: 2011 ident: B36 article-title: Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. publication-title: Arch. Gen. Psychiatry doi: 10.1001/archgenpsychiatry.2010.116 – volume: 593 start-page: 49 year: 2009 ident: B37 article-title: Effects of chronic citalopram treatment on 5-HT1A and 5-HT2A receptors in group- and isolation-housed mice. publication-title: Eur. J. Pharmacol. doi: 10.1016/j.ejphar.2008.07.011 – volume: 50 start-page: 121 year: 2021 ident: B54 article-title: Psilocybin-induced changes in brain network integrity and segregation correlate with plasma psilocin level and psychedelic experience. publication-title: Eur. Neuropsychopharmacol. doi: 10.1016/j.euroneuro.2021.06.001 – volume: 141 start-page: 106 year: 2012 ident: B43 article-title: Mindfulness training affects attention-Or is it attentional effort? publication-title: J. Exp. Psychol. Gen. doi: 10.1037/a0024931 – volume: 11 start-page: 245 year: 2017 ident: B56 article-title: Looking for the self: Phenomenology, neurophysiology and philosophical significance of drug-induced ego dissolution. publication-title: Front. Hum. Neurosci. doi: 10.3389/fnhum.2017.00245 – volume: 9 start-page: 14914 ident: B71 article-title: Characterization and prediction of acute and sustained response to psychedelic psilocybin in a mindfulness group retreat. publication-title: Sci. Rep. doi: 10.1038/s41598-019-50612-3 – volume: 235 start-page: 2979 year: 2018 ident: B80 article-title: Sub-acute and long-term effects of ayahuasca on affect and cognitive thinking style and their association with ego dissolution. publication-title: Psychopharmacology (Berl.) doi: 10.1007/s00213-018-4988-3 – volume: 6 start-page: 537 year: 2011 ident: B41 article-title: How does mindfulness meditation work? Proposing mechanisms of action from a conceptual and neural perspective. publication-title: Perspect. Psychol. Sci. doi: 10.1177/1745691611419671 – volume: 9 start-page: 1475 year: 2018 ident: B57 article-title: Psychedelics, meditation, and self-consciousness. publication-title: Front. Psychol. doi: 10.3389/fpsyg.2018.01475 – volume: 12 start-page: 707057 year: 2021 ident: B20 article-title: Examining the potential synergistic effects between mindfulness training and psychedelic-assisted therapy. publication-title: Front. Psychiatry doi: 10.3389/fpsyt.2021.707057 – volume: 25 start-page: 1453 year: 2011 ident: B51 article-title: Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. publication-title: J. Psychoph. doi: 10.1177/0269881111420188 – volume: 78 start-page: 481 year: 2021 ident: B19 article-title: Effects of psilocybin-assisted therapy on major depressive disorder: A randomized clinical trial. publication-title: JAMA Psychiatry doi: 10.1001/jamapsychiatry.2020.3285 – volume: 143 start-page: 101 year: 2021 ident: B1 article-title: Therapeutic effects of classic serotonergic psychedelics: A systematic review of modern-era clinical studies. publication-title: Acta Psychiatr. Scand. Scand. doi: 10.1111/acps.13249 – volume: 13 start-page: 27 year: 2006 ident: B3 article-title: Using self-report assessment methods to explore facets of mindfulness. publication-title: Assessment doi: 10.1177/1073191105283504 – volume: 130 start-page: 167 year: 2016 ident: B23 article-title: Serotonin 2A receptor agonist binding in the human brain with [11C]Cimbi-36: Test–retest reproducibility and head-to-head comparison with the antagonist [18F]altanserin. publication-title: Neuroimage doi: 10.1016/j.neuroimage.2016.02.001 – volume: 29 start-page: 1182 year: 2015 ident: B5 article-title: Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin. publication-title: J. Psychopharmacol. doi: 10.1177/0269881115609019 – volume: 33 start-page: 1088 year: 2019 ident: B28 article-title: Cessation and reduction in alcohol consumption and misuse after psychedelic use. publication-title: J. Psychopharmacol. doi: 10.1177/0269881119845793 – volume: 22 start-page: 621 year: 2008 ident: B34 article-title: Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. publication-title: J. Psychopharmacol. doi: 10.1177/0269881108094300 – year: 2018 ident: B62 article-title: Phenomenology, structure, and dynamic of psychedelic states publication-title: Behavioral Neurobiology of Psychedelic Drugs. Current Topics in Behavioral Neurosciences doi: 10.1007/7854_2016_459 – year: 2002 ident: B67 publication-title: Mindfulness- based cognitive therapy for depression: A new approach to preventing relapse. – volume: 38 start-page: 179 year: 2006 ident: B40 article-title: Relationships between meditation depth, absorption, meditation practice, and mindfulness: A latent variable approach. publication-title: J. Transpers. Psychol. – year: 1988 ident: B18 publication-title: Statistical power analysis for the behavioral sciences – volume: 84 start-page: 822 year: 2003 ident: B10 article-title: The benefits of being present: Mindfulness and its role in psychological well-being. publication-title: J. Pers. Soc. Psychol. doi: 10.1037/0022-3514.84.4.822 – volume: 63 start-page: 569 year: 2008 ident: B27 article-title: Frontolimbic serotonin 2A receptor binding in healthy subjects is associated with personality risk factors for affective disorder publication-title: Biol. Psychiatry doi: 10.1016/j.biopsych.2007.07.009 – volume: 37 start-page: 425 year: 2018 ident: B46 article-title: Cerebral 5-HT release correlates with [11C]Cimbi36 PET measures of 5-HT2A receptor occupancy in the pig brain. publication-title: J. Cereb. Blood Flow Metab. doi: 10.1177/0271678X16629483 – volume: 56 start-page: 441 year: 2001 ident: B30 article-title: Paradoxical trafficking and regulation of 5-HT(2A) receptors by agonists and antagonists. publication-title: Brain Res. Bull. doi: 10.1016/S0361-9230(01)00623-2 – volume: 109 start-page: 2138 year: 2012 ident: B15 article-title: Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. publication-title: Proc. Natl. Acad. Sci. U.S.A. doi: 10.1073/pnas.1119598109 – volume: 33 start-page: 71 year: 2020 ident: B53 article-title: A single psilocybin dose is associated with long-term increased mindfulness, preceded by a proportional change in neocortical 5-HT2A receptor binding. publication-title: Eur. Neuropsychopharmacol. doi: 10.1016/j.euroneuro.2020.02.001 – volume: 67 start-page: 267 year: 2011 ident: B68 article-title: The moderation of Mindfulness-based stress reduction effects by trait mindfulness: Results from a randomized controlled trial. publication-title: J. Clin. Psychol. doi: 10.1002/jclp.20761 – year: 1960 ident: B75 publication-title: The teachings of the mystics. – volume: 30 start-page: 1181 year: 2016 ident: B31 article-title: Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. publication-title: J. Psychopharmacol. doi: 10.1177/0269881116675513 – volume: 43 start-page: 55 year: 2017 ident: B44 article-title: Long-term Follow-up of Psilocybin-facilitated Smoking Cessation. publication-title: Am. J. Drug Alcohol Abuse doi: 10.3109/00952990.2016.1170135 – volume: 84 start-page: 342 year: 2014 ident: B25 article-title: Characterization of [11C]Cimbi-36 as an agonist PET radioligand for the 5-HT2A and 5-HT2C receptors in the nonhuman primate brain. publication-title: Neuroimage doi: 10.1016/j.neuroimage.2013.08.035 – volume: 218 start-page: 649 year: 2011 ident: B33 article-title: Psilocybin occasioned mystical-type experiences: Immediate and persisting dose-related effects. publication-title: Psychopharmacology (Berl.) doi: 10.1007/s00213-011-2358-5 – volume: 10 start-page: e0127447 year: 2015 ident: B11 article-title: Association between Mindfulness and weight status in a general population from the NutriNet-Santé study. publication-title: PLoS One doi: 10.1371/journal.pone.0127447 – volume: 9 start-page: 3897 year: 1998 ident: B81 article-title: Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. publication-title: Neuroreport doi: 10.1097/00001756-199812010-00024 |
| SSID | ssj0000402002 |
| Score | 2.4301147 |
| Snippet | Psilocybin-induced mystical-type experiences are associated with lasting positive psychological outcomes. Recent studies indicate that trait mindfulness is... BackgroundPsilocybin-induced mystical-type experiences are associated with lasting positive psychological outcomes. Recent studies indicate that trait... |
| SourceID | doaj pubmedcentral proquest pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 948729 |
| SubjectTerms | [11C]-Cimbi-36 mindfulness mystical experience psilocybin psychedelics Psychology serotonin 2A receptor |
| Title | Lasting increases in trait mindfulness after psilocybin correlate positively with the mystical-type experience in healthy individuals |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/36275302 https://www.proquest.com/docview/2728146362 https://pubmed.ncbi.nlm.nih.gov/PMC9580465 https://doaj.org/article/a8431aa8fb25453c942dc767ced87af9 |
| Volume | 13 |
| WOSCitedRecordID | wos000874184900001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: Directory of Open Access Journals customDbUrl: eissn: 1664-1078 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000402002 issn: 1664-1078 databaseCode: DOA dateStart: 20100101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1664-1078 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000402002 issn: 1664-1078 databaseCode: M~E dateStart: 20100101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELag4tAL4s1SqIzECSk0cZw4PgJqxaFUHADtzfITIm3TVb1bKRdu_O_O2NuwixBcuERR4iTWzNjzfc54hpBXglldSt0U4IxMwW3pC0DhbWEcXK40b3NsztdTcXbWzefy01apL4wJy-mBs-COdAcuTusuGKAyTW0lZ86KVljvOqFD2rpXCrlFptIcjLSoZPk3JrAweRSWcfwGfJCxNxJAeoKUvxxRytf_J5D5e6zklvM5uUfublAjfZt7e5_c8sMDsj9NXuND8vNUR4xgpv2AODD6CGcUC0Cs6Dnw7rBe4KRGU01wuow9OLERWDG1WJ5jAYiT5vitK78YKa7OUoCG9HyMabG7wKVa6qe8yPjyvIVypP20pys-Il9Ojj-__1BsSiwUlrfNqjCBddoIy4VGZlKBkLVnXQiMGWcqx5ltHTPMNrIVwtjKSy1cqMrguZZO14_J3nAx-KeEhiCM803NuQXW1XHpWwtotAmN5g4w_IyUN_JWdpN_HKWwUMBDUEUqqUihilRW0Yy8nh5Z5uQbf2v8DpU4NcS82ekCWJPaWJP6lzXNyMsbE1AwzvDniR78xToqJhiuloK_n5En2SSmT9WY6rku4Y7YMZadvuzeGfrvKZe3bLoSNPHsf3T-gOyjPFKoYfOc7K0u1_4FuWOvVn28PCS3xbw7TMMEjh9_HF8DncMezg |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Lasting+increases+in+trait+mindfulness+after+psilocybin+correlate+positively+with+the+mystical-type+experience+in+healthy+individuals&rft.jtitle=Frontiers+in+psychology&rft.au=S%C3%B8ndergaard%2C+Anna&rft.au=Madsen%2C+Martin+Korsbak&rft.au=Ozenne%2C+Brice&rft.au=Armand%2C+Sophia&rft.date=2022-10-05&rft.issn=1664-1078&rft.eissn=1664-1078&rft.volume=13&rft.spage=948729&rft_id=info:doi/10.3389%2Ffpsyg.2022.948729&rft_id=info%3Apmid%2F36275302&rft.externalDocID=36275302 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1664-1078&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1664-1078&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1664-1078&client=summon |